Cargando…

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522660/
https://www.ncbi.nlm.nih.gov/pubmed/33014513
_version_ 1783588232085110784
collection PubMed
description
format Online
Article
Text
id pubmed-7522660
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-75226602020-10-01 Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management J Adv Pract Oncol CE Information Harborside Press LLC 2019-03 2019-03-01 /pmc/articles/PMC7522660/ /pubmed/33014513 Text en © 2019 Harborside™ http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle CE Information
Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
title Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
title_full Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
title_fullStr Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
title_full_unstemmed Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
title_short Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
title_sort advances in her2-positive breast cancer: novel therapies and adverse event management
topic CE Information
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522660/
https://www.ncbi.nlm.nih.gov/pubmed/33014513